<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399046</url>
  </required_header>
  <id_info>
    <org_study_id>DPS-201302</org_study_id>
    <nct_id>NCT02399046</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Study of Knee System in Primary Total Knee Arthroplasty in China</brief_title>
  <official_title>A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Medical (Suzhou) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Medical (Suzhou) Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of total knee system used in Primary Total Knee Arthroplasty in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary
      Total Knee Arthroplasty Devices Manufactured in China versus Devices Manufactured Outside of
      China.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month post-op AKS</measure>
    <time_frame>12 months postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-revision rates(revision for any reason) through the end of the study</measure>
    <time_frame>12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year non-revision rate where revision is defined as removal of any component secondary to infection</measure>
    <time_frame>12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Knee Society Total Score success (where success is defined as a score of 80 points or higher)at the 1 year follow-up inerval</measure>
    <time_frame>12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-form 12(SF-12) general health questionnaire each of 8 dimensions and the overall Physical and Mental health domains, at 1-year follow-up interval.</measure>
    <time_frame>Preoperation to12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC scores at the 1-year follow-up interval</measure>
    <time_frame>Preoperation to12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiogrphic assessment of clinically relevant radiolucent line(RLL)and osteolysis,migration and subsidence, by comparing the 3 month post-operative x-ray to the 1 year follow up x-ray inerval.</measure>
    <time_frame>Preoperation to12 months postoperatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The proportion of Composite Successes in each treatment group will be assessed at the 1year follow-up interval</measure>
    <time_frame>12 months postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood samplets will be collected and data will be summarized</measure>
    <time_frame>pre-operative and immediate post-operatively</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Osteoarthritis</condition>
  <condition>Post-traumatic; Arthrosis</condition>
  <arm_group>
    <arm_group_label>Total Knee System made in China</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Knee System made outside of China</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Knee System made in China (Sigama, CoCr, PFC)</intervention_name>
    <description>SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG</description>
    <arm_group_label>Total Knee System made in China</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Knee System made outside of China (Sigama, NP, PFC)</intervention_name>
    <description>SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT</description>
    <arm_group_label>Total Knee System made outside of China</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. . The subject is ≥18years old

          2. . The Subject must be of Chinese ethnic descent and be willing to return on three
             occasions for clinical evaluations.

          3. . Subject is a suitable candidate for cemented primary TKA using the devices described
             in this CIP with either resurfaced or non-resurfaced patellae.

          4. . Subject must meet all criteria specified in BOTH China Knee stem and P.F.C.® Sigma
             knee instructions for use (IFU)

          5. . Before surgery, subject is willing and able to sign the informed consent form
             approved by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical
             Review Board (ERB).

          6. . Subject, in the opinion of the Clinical Investigator, is able to understand this
             clinical investigation and co-operate with investigational procedures.

          7. . Subject must be comfortable with speaking, reading, and understanding questions and
             providing responses in an available translated language for the patient reported
             outcomes (PROs) in the CIP.

          8. . Subject is receiving a unilateral knee replacement or, if a contralateral knee
             replacement is anticipated, the surgery must occur within 6 months of the first study
             knee TKA. The second knee will not be enrolled in the study.

        Exclusion Criteria:

          1. Subject does not provide written voluntary consent to participate in the clinical
             study.

          2. The Subject is a woman who is pregnant or lactating.

          3. Subject is anticipated to require a contralateral TKA between 6 months and 1 year.

          4. Contralateral knee has already been enrolled in this study.

          5. Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral
             joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected
             knee.

          6. Subject has a malignant disease, severe condition, alcohol or drug addiction and/or
             mental disorders that the investigator believes will interfere with the study
             participation.

          7. Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or
             tumor in bone surrounding knee joint that, in the opinion of the investigator, will
             negatively impact implant fixation and the outcome of the investigation

          8. Subject has significant neurological or musculoskeletal disorders or disease that may
             adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis,
             cerebral infarction, hemiplegia, Charcot disease).

          9. Subject is not comfortable with speaking, reading, and understanding questions and
             providing responses in an available translated language for the PROs in the CIP.

         10. Subject has a medical condition with less than 2 years of life expectancy.

         11. The Subject has comorbid condition(s) that could limit the Subject's ability to
             participate in the study, compliance with follow-up requirements or impact the
             scientific integrity of the study.

         12. The Subject is currently participating in another investigational drug or device
             study.

         13. Subject is a prisoner.

         14. The Subject has a known allergy to any implant components (metal for example).

         15. Hemoglobin &lt; 11 g/L

         16. Albumin &lt; 90% normal low limit

         17. CRP &gt; 2 times normal upper limit

         18. ESR &gt; 2 times normal upper limit

         19. Subjects who have abnormal coagulation exam results and cannot be corrected by drugs
             or plasma replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuxing Pei</last_name>
    <role>Principal Investigator</role>
    <affiliation>The West China Hospital of Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fuxing Pei</last_name>
    <phone>+86 18980601380</phone>
    <email>peifuxing@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zongsheng Yin</last_name>
      <phone>+86 13956977198</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xisheng Weng</last_name>
      <phone>+86 13366200018</phone>
      <email>xshweng@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Guangzhou Military Command of PLA</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Zhang</last_name>
      <phone>+86 13602744495</phone>
      <email>luck_2001@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihe Hu</last_name>
      <phone>+86 13973184588</phone>
      <email>xy_huyh@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The affiliated hosoital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qunhua Jin</last_name>
      <phone>+86 13709593699</phone>
      <email>jinqunhua@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingzhen Wang</last_name>
      <phone>+86 18661808238</phone>
      <email>18661808238@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingsheng Zhu</last_name>
      <phone>+86 13909271862</phone>
      <email>zhuqsh@fmmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Yang</last_name>
      <phone>+86 13708034450</phone>
      <email>cd-yangjing@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Teaching Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Cao</last_name>
      <email>xjbone@21cn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

